|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
In 2015, to recognize the extraordinary contributions of Dr. London, the Blumberg Institute
created the W. Thomas London Distinguished Professorship. At the ceremony to celebrate the
named professorship, 2020 Nobel Prize winner Harvey Alter, MD, eminent scientist at the NIH
and co-discoverer of the hepatitis B virus (and C virus), described the seminal contributions of
Dr. London as "world changing in magnitude, but done quietly, and modestly."
Upon its establishment five years ago, Ju-Tao Guo, MD, assumed the Chair of the W. Thomas
London Distinguished Professorship. A professorship is the highest academic award an
institution can bestow on a faculty member, and Dr. Guo embodies the scholarship and
highest standards of rigor that it confers.
Dr. Guo received his medical training in Lanzhou University School of Medicine in China and
postdoctoral training with Blumberg Prize winner Dr. Christoph Seeger at Fox Chase CancerCenter in Philadelphia. Dr. Guo has been working on the molecular pathogenesis and antiviral
research of hepatitis viruses, flaviviruses and human coronaviruses in the past thirty years and
published more than 90 peer-reviewed research papers, review articles, commentaries and
book chapters in the related fields.
Major achievements in the last five years at Dr. Ju-Tao Guo’s Laboratory
With the support of the National Institutes of Health, Department of Defense, Arbutus Biopharma and the W. Thomas London
Distinguished Professorship
• Host cellular proteins required for key steps of HBV replication, such as pre-genomic
RNA packaging and synthesis of covalently closed circular (ccc) DNA, have been
identified.
• Interferon alpha-induced cellular proteins that epigenetically suppress the
transcription of cccDNA minichromosome have been discovered.
• HBV capsid assembly modulators, including the compounds discovered from our
laboratory, are currently in preclinical and clinical development for treatment of
chronic hepatitis B. The lab’s scientists found that this class of compounds not only
disrupts capsid assembly, but also induces the premature disassembly of HBV
nucelocapsids, which results in the inhibition of cccDNA synthesis. Therefore, the
CAMs inhibit HBV replication via dual mechanisms.
• A structural motif of HBV small envelope protein essential for the morphogenesis of
subviral particles (SVP) has been identified, which paves the way for the discovery of
antiviral agents that can specifically inhibit SVP production and facilitate the
functional cure of chronic hepatitis B.
• The lab’s scientists have demonstrated that activation of STING in both macrophages
and hepatocytes efficiently suppresses HBV replication and they have discovered two
chemotypes of small molecular human STING agonists for further preclinical
development.
Dr. Guo was also featured during a recent “Insider Experience – Year in Review” webinar,
hosted by our President, Dr. Timothy M. Block. You can view that recording HERE.
Additional projects being undertaken in Blumberg |
|
发表于 2020-12-9 14:16
